SAREPTA THERA INC revenue breakdown overview

SAREPTA THERA INC revenue for the last year amounted to 1.73 B CHF, the most of which — 1.62 B CHF — came from its highest performing source at the moment, RNA-targeted Therapeutics, Gene Therapy and Other Genetic Therapeutic Modalities, the year earlier bringing 963.91 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought SAREPTA THERA INC 1.49 B CHF, and the year before that — 840.50 M CHF.